Key result
Avatrombopag is superior to placebo in reducing the need for platelet transfusions or rescue procedures for bleeding in patients with chronic liver disease scheduled for a procedure.
Why the study?
Thrombocytopenia is common in chronic liver disease and increases bleeding risk, which potentially complicates clinical management such as surgery or liver biopsy.
Does avatrombopag reduce the need for platelet transfusions or rescue procedures for bleeding in patients with chronic liver disease and thrombocytopenia scheduled for a procedure?
Does avatrombopag reduce the need for platelet transfusions or rescue procedures for bleeding in patients with chronic liver disease and thrombocytopenia scheduled for a procedure?
Avatrombopag is an effective alternative to platelet transfusions for managing thrombocytopenia in patients with chronic liver disease undergoing procedures.
Introduction: Thrombocytopenia is a common hematological abnormality in patients with chronic liver disease (CLD), occurring in 64%~84% of patients with cirrhosis or fibrosis. Due to the increased risk of bleeding, thrombocytopenia potentially affects management of CLD, such as surgery or liver biopsy. Avatrombopag is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.Areas covered: This review summarizes the collected data concerning pharmacokinetics, clinical efficacy, safety and tolerability profiles of avatrombopag for the management of thrombocytopenia in patients with CLD.Expert opinion: Avatrombopag is recently approved by Food and Drug Administration (FDA) for the treatment of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure. Based on the available clinical trials, avatrombopag is superior to placebo in reducing the need for platelet transfusions or rescue procedures for bleeding. Avatrombopag is also recommended as alternative to platelet transfusions.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2019) conducted a review in Thrombocytopenia in patients with chronic liver disease. Avatrombopag vs. Placebo was evaluated on Need for platelet transfusions or rescue procedures for bleeding. Avatrombopag is superior to placebo in reducing the need for platelet transfusions or rescue procedures for bleeding in patients with chronic liver disease scheduled for a procedure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: